Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECC 5004

Next Previous
X
Search
Drug Profile

ECC 5004

Alternative Names: AZD-5004; ECC-5004

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; Eccogene
  • Developer Eccogene
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Sep 2024 AstraZeneca plans phase II SOLSTICE trial in Type 2 diabetes mellitus in US, Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain and United Kingdom in October 2024 (PO) (NCT06579105)
  • 04 Sep 2024 AstraZeneca plans phase II VISTA trial in Obesity in US, Australia, Canada, Germany, Taiwan and United Kingdom in October 2024 (PO)(NCT06579092)
  • 21 Aug 2024 AstraZeneca plans a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06555822)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top